Chiron Optimistic About Re-entering U.S. Flu Vaccine Market In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. Medicines & Healthcare Products Regulatory Agency extends suspension of Chiron's license to manufacture Fluvirin by three months, the company says. The extension can be "lifted at any time" once Chiron rectifies the problems at its Liverpool facility, MHRA says.